drugset / Trial / NCT00096629
Vaccine Therapy in Treating Patients With Kidney Cancer
Phase 1
Completed
15 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
RandomizedCrossoverOpen-labelTreatment
Summary
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with kidney cancer.
Timeline
- Start
- 2003-11
- Primary completion
- 2018-04
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human prostate-specific membrane antigen plasmid DNA vaccine | Vaccine | — | Intramuscular |
| Subject | mouse prostate-specific membrane antigen plasmid DNA vaccine | Vaccine | — | Intramuscular |